Relmada Therapeutics, Inc. RLMD Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Relmada Therapeutics, Inc. (RLMD) reported deferred tax assets, valuation allowance of $122.5M in Q4 2025.
- How has Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance changed year-over-year?
- Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance increased by 6.2% year-over-year, from $115.36M to $122.5M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s deferred tax assets, valuation allowance has grown at a 19.4% compound annual growth rate (CAGR), from $50.42M to $122.5M.